Avacopan information

Avacopan
Clinical data
Trade names	Tavneos
Other names	CCX168
AHFS/Drugs.com	Monograph
MedlinePlus	a622023
License data	US DailyMed: Avacopan;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
Drug class	Complement C5a receptor antagonist
ATC code	L04AJ05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; Rx-only;
Identifiers
CAS Number	1346623-17-3;
PubChem CID	49841217;
DrugBank	DB15011;
ChemSpider	52083514;
UNII	O880NM097T;
KEGG	D11093;
ChEMBL	ChEMBL3989871;
PDB ligand	EFD (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID701102660 ;
ECHA InfoCard	100.351.344
Chemical and physical data
Formula	C33H35F4N3O2
Molar mass	581.656 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=C(NC(=O)[C@H]2CCCN([C@H]2C2=CC=C(NC3CCCC3)C=C2)C(=O)C2=C(F)C=CC=C2C)C=C1C(F)(F)F;
	InChI InChI=1S/C33H35F4N3O2/c1-20-12-15-25(19-27(20)33(35,36)37)39-31(41)26-10-6-18-40(32(42)29-21(2)7-5-11-28(29)34)30(26)22-13-16-24(17-14-22)38-23-8-3-4-9-23/h5,7,11-17,19,23,26,30,38H,3-4,6,8-10,18H2,1-2H3,(H,39,41)/t26-,30-/m0/s1; Key:PUKBOVABABRILL-YZNIXAGQSA-N;

Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis.^[5]^[6]^[8] Avacopan is a complement 5a receptor antagonist^[5] and a cytochrome P450 3A4 inhibitor.^[5]

The most common side effects include nausea (feeling sick), headache, decrease in white blood cell count, upper respiratory tract (nose and throat) infection, diarrhea, vomiting, and nasopharyngitis (inflammation of the nose and throat).^[6]

Avacopan was approved for medical use in Japan in September 2021,^[7] and in the United States in October 2021.^[5]^[8]^[9] It is the first orally-administered inhibitor of the complement C5a receptor approved by the US Food and Drug Administration (FDA).^[8] The FDA considers it to be a first-in-class medication.^[10]

^ ^a ^b "Archived copy". Archived from the original on 2 January 2024. Retrieved 2 January 2024.{{cite web}}: CS1 maint: archived copy as title (link)
^ "Tavneos (Vifor Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 29 April 2023.
^ "Summary Basis of Decision - Tavneos". Health Canada. 28 July 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.
^ "Tavneos (Avacopan) Summary of Product Characteristics (SmPC)". emc. 26 May 2022. Archived from the original on 24 July 2023. Retrieved 23 July 2023.
^ ^a ^b ^c ^d ^e "Tavneos- avacopan capsule". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
^ ^a ^b ^c Cite error: The named reference Tavneos EPAR was invoked but never defined (see the help page).
^ ^a ^b "ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Archived from the original on 9 October 2021. Retrieved 11 October 2021.
^ ^a ^b ^c "ChemoCentryx Announces FDA Approval of Tavneos (avacopan) in ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 8 October 2021. Archived from the original on 8 October 2021. Retrieved 11 October 2021.
^ "Drug Approval Package: Tavneos". U.S. Food and Drug Administration (FDA). 4 November 2021. Archived from the original on 7 May 2022. Retrieved 7 May 2022.
^ Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

[Tavneos_APMDS-1] "Archived copy". Archived from the original on 2 January 2024. Retrieved 2 January 2024.{{cite web}}: CS1 maint: archived copy as title (link)

[2] "Tavneos (Vifor Pharma Pty Ltd)". Therapeutic Goods Administration (TGA). 16 February 2023. Archived from the original on 27 March 2023. Retrieved 29 April 2023.

[3] "Summary Basis of Decision - Tavneos". Health Canada. 28 July 2022. Archived from the original on 29 September 2022. Retrieved 29 September 2022.

[4] "Tavneos (Avacopan) Summary of Product Characteristics (SmPC)". emc. 26 May 2022. Archived from the original on 24 July 2023. Retrieved 23 July 2023.

[Tavneos_FDA_label-5] "Tavneos- avacopan capsule". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.

[Tavneos_EPAR-6] Cite error: The named reference Tavneos EPAR was invoked but never defined (see the help page).

[ChemoCentryx_PR_20210927-7] "ChemoCentryx Announces Approval in Japan of Tavneos (Avacopan) for the Treatment of ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 27 September 2021. Archived from the original on 9 October 2021. Retrieved 11 October 2021.

[ChemoCentryx_PR-8] "ChemoCentryx Announces FDA Approval of Tavneos (avacopan) in ANCA-Associated Vasculitis". ChemoCentryx, Inc. (Press release). 8 October 2021. Archived from the original on 8 October 2021. Retrieved 11 October 2021.

[9] "Drug Approval Package: Tavneos". U.S. Food and Drug Administration (FDA). 4 November 2021. Archived from the original on 7 May 2022. Retrieved 7 May 2022.

[New_Drug_Therapy_Approvals_2021-10] Advancing Health Through Innovation: New Drug Therapy Approvals 2021 (PDF). U.S. Food and Drug Administration (FDA) (Report). 13 May 2022. Archived from the original on 6 December 2022. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.

Avacopan information

and 5 Related for: Avacopan information

Avacopan

Avacincaptad pegol

ATC code L04

CSL Vifor

Outline of immunology